N4 Pharma Plc (LON:N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments and vaccines, has provided an update on its ongoing Australian Research Council grant
N4 Pharma Plc (LON:N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments and vaccines, has provided an opportunity for shareholders and other investors who did
N4 Pharma Plc (LON:N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments and vaccines, has announced that it has raised £1 million (before expenses) through
N4 Pharma Plc (LON:N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments and vaccines, has provided an update on its patent application for Nuvec®, filed
N4 Pharma Plc (LON:N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments and vaccines, has announced successful in vitro testing of Nuvec® loaded with two small interfering RNA
N4 Pharma Plc (LON:N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for vaccines and cancer treatments, has announced its unaudited interim results for the six months ended 30
N4 Pharma’s Nigel Theobald discusses highlights from their operational update, SiRNA, the strong commercial points of difference for Nuvec and what’s next for the company in this exclusive interview with DirectorsTalk.
N4 Pharma plc (LON:N4P) CEO Nigel Theobald chats to DirectorsTalk Interviews about its development plans for commercialising Nuvec. Nigel talks us through the update highlights, explains why companies working with siRNA
N4 Pharma Plc (LON:N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments and vaccines, has provided an operational update on its development plans for commercialising Nuvec®.
N4 Pharma Plc (LON:N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments and vaccines, has announced a further update on its recent pre-clinical study with
© 2022 – DirectorsTalk. All rights reserved. Reproduction in whole or in part, in any form or medium without express written permission is prohibited.
